Certified Advisory Corp Has $2.99 Million Stake in Eli Lilly and Company (NYSE:LLY)

Key Points

• Certified Advisory Corp reduced its stake in Eli Lilly and Company by 10.5%, selling 422 shares during the first quarter, leaving them with 3,614 shares valued at approximately $2.98 million.
• Eli Lilly reported quarterly earnings of $3.34 EPS, missing analysts' expectations by $1.30, although its revenue of $12.73 billion was close to projections.
• The company recently announced a quarterly dividend of $1.50 per share, representing a 0.8% yield and a dividend payout ratio of 48.82%.

Certified Advisory Corp lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,614 shares of the company's stock after selling 422 shares during the quarter. Certified Advisory Corp's holdings in Eli Lilly and Company were worth $2,985,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. WestEnd Advisors LLC increased its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the period. Citizens National Bank Trust Department boosted its stake in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $40,000. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $43,000. Finally, O Brien Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price on the stock. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Finally, Guggenheim upped their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $1,012.56.

Eli Lilly and Company Trading Up 2.9%

NYSE:LLY traded up $21.40 during trading hours on Friday, hitting $761.47. The stock had a trading volume of 4,857,388 shares, compared to its average volume of 3,285,034. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company has a market cap of $721.67 billion, a price-to-earnings ratio of 61.96, a P/E/G ratio of 1.05 and a beta of 0.44. The business's 50 day moving average is $775.51 and its 200-day moving average is $799.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the company posted $2.58 EPS. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.